Cancer combo trial halted early: what we know

NCT ID NCT05846659

Terminated Disease control Sponsor: ImmuneSensor Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested whether adding an experimental drug called IMSA101 to standard immunotherapy and a special type of radiation (PULSAR) could help control cancer in people with solid tumors that had started to grow again after prior treatment. Only 16 patients were enrolled before the study was terminated early, so the results are not conclusive. The goal was to see if the combination could prevent further cancer progression for at least 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMSA101 (a STING agonist injected into tumors), plus pembrolizumab or nivolumab (immunotherapy drugs), plus PULSAR (a type of radiation therapy)
What this could lead to: If it works, this could point toward a way to slow or stop cancer growth in patients whose tumors have started to progress despite other treatments.
What could go wrong: The trial was terminated early with only 16 participants, so results are very limited. It is unclear if the combination is safe or effective, and side effects from the drugs and radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OLIGOPROGRESSIVE

Contacts and locations

Show contact details

Locations

Baylor College of Medicine Medical Center

Houston, Texas, 77030, United States
Brigham and Women's Hospital/Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Louis Stokes Cleveland VA Medical Center

Cleveland, Ohio, 44106, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
UCLA

Los Angeles, California, 90095, United States
USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Wisconsin Hospital and Clinics

Madison, Wisconsin, 53792, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.